A research dataset from figshare, authored by Xiaoling Tian and last updated in April 2026, exploring the role of adenosine deaminase (ADA) in esophageal cancer. The dataset likely contains results from a multi-level integrative analysis, including two-sample Mendelian randomization, serum validation, transcriptomic analysis, and single-cell RNA sequencing. It identifies ADA as a potential risk factor and explores intervention strategies via reverse network pharmacology.
Use Cases
- Validate genetic associations based on Mendelian randomization odds ratios mentioned in the description
- Analyze co-expression network enrichment based on pathways like 'proteasome' and 'protein folding'
- Investigate cell-type-specific expression patterns based on single-cell RNA sequencing results for plasma cells and plasmacytoid dendritic cells
- Screen for potential drug compounds based on the identified lead compounds catechin and flavoxanthin
Strengths
- Includes results from a multi-method analysis integrating Mendelian randomization, serum validation, and single-cell sequencing
- Identifies a specific odds ratio (OR = 1.23) for ADA as a potential risk factor for esophageal cancer
- Released under a permissive CC-BY-4.0 license for open reuse
Limitations
- Column-level documentation is absent; field semantics must be inferred after download
- Row count is unknown, which may limit suitability assessment
- The 247.0 KB file size suggests a limited scope, likely containing summary results rather than raw experimental data
Provenance
- Source
- figshare, author Xiaoling Tian
- Collection Method
- Multi-level integrative analysis including Mendelian randomization, serum validation, transcriptomic analysis, co-expression network enrichment, single-cell RNA sequencing, reverse network pharmacology, and molecular docking simulation.
- Time Range
- null
- Freshness
- Last updated 2026-04 23 04:21:41; freshness should be verified
- Geography
- null